This represents an average additional fat loss of about 1.8 kg (4 pounds) over 12 weeks attributable to the peptide
Providing anti-inflammatory effects Data showed that NNMT increases collagens and inflammatory molecules, which worsen inflammation

Comparison to semaglutide and tirzepatide Head-to-head effectiveness: Tesofensine advantages: Boosts metabolism (GLP-1s don't) Rapid onset ( hours vs days ) Less GI side effects (no nausea) Oral administration (vs injection for GLP-1s ) Cheaper (research chemical pricing) Tesofensine disadvantages: Cardiovascular risks (heart rate, BP) Stimulant-like effects (dependency potential) Not FDA approved (legal concerns) Limited long-term safety data Higher dropout rates in trials Why GLP-1s preferred clinically: FDA approved (safe, legal) Cardiovascular benefits (tesofensine has risks) Better long-term safety profile No dependency/tolerance issues More comprehensive clinical data When tesofensine might be considered: GLP-1 intolerance (severe nausea ) Desire for metabolic boost Research/experimental use only Combined with other interventions Under medical supervision Learn about semaglutide vs tirzepatide and best weight loss stacks

It was developed by Metabolic Pharmaceuticals, an Australian biopharmaceutical company, in the late 1990s as a potential therapeutic for obesity and metabolic disorders
Small molecule CD38 inhibitors To date, over 200 compounds are listed as CD38 inhibitors in the literature [40, 54, 58-60, 65-78]